Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 75INDUSTRY 55NIH 12NETWORK 3OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Head & Neck 1Dermatologic 1

Conditions

Refractory Differentiated Thyroid Gland Carcinoma 1Melanoma 1Glioma 1Brain Neoplasms 1

Interventions

Radiotherapy 302Cisplatin 266Cyclophosphamide 230Doxorubicin 177Paclitaxel 170Vincristine 162Carboplatin 152Filgrastim 140Etoposide 139Gemcitabine 118Docetaxel 114Fluorouracil 113Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 92Leucovorin 90Gene Expression Profiling 82Granulocyte Colony-Stimulating Factor 75Specimen Handling 70Magnetic Resonance Spectroscopy 63Irinotecan 59Capecitabine 59Radiation 54Polymerase Chain Reaction 51Ifosfamide 51Rituximab 49Immunohistochemistry 49Daunorubicin 49Oxaliplatin 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × dabrafenib × Clear all
NCT06475989 2026-05-15

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Eastern Cooperative Oncology Group

Phase 3 Recruiting
264 enrolled
Head & Neck

Refractory Differentiated Thyroid Gland Carcinoma

NCT04201457 2026-02-03

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

Pediatric Brain Tumor Consortium

Phase 1/2 Active not recruiting
57 enrolled
CNS

Glioma

NCT02974803 2021-08-20

Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases

Canadian Cancer Trials Group

Phase 2 Terminated
6 enrolled 3 charts
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡